| Literature DB >> 9871745 |
D Dubé1, M Blouin, C Brideau, C C Chan, S Desmarais, D Ethier, J P Falgueyret, R W Friesen, M Girard, Y Girard, J Guay, D Riendeau, P Tagari, R N Young.
Abstract
Leukotriene biosynthesis inhibitors have potential as new therapeutic agents for asthma and inflammatory diseases. A series of novel substituted 2-cyanoquinolines have been synthesized and the structure activity relationships were evaluated with respect to their ability to inhibit the formation of leukotrienes via the 5-lipoxygenase enzyme. [1S,5R]-2-Cyano-4-(3-furyl)-7-¿3-fluoro-5-[3-(3 alpha-hydroxy-6,8-dioxabicyclo[3.2.1]-octanyl)]phenoxymethyl ¿quinoline (L-746,530) 3 represents a distinct class of inhibitors and possesses in vitro and in vivo potency comparable or superior to naphthalenic analog (L-739,010) 2.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9871745 DOI: 10.1016/s0960-894x(98)00201-7
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823